Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10

Contributed by: PR Newswire

Tags

Kexing-Biopharm

More Like This

Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global Expansion

Kexing Biopharm made its appearance at CPHI Milan 2024: Launch Ceremony for Apexelsin® in EU market Successfully done

Kexing Biopharm Attended CPHI Worldwide 2023

2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm's Series of Globalization Activities (China) Successfully Concluded

R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026

Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025

PR Newswire associated0

Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema